Codex @codex  0

A bioactive glass is a glass designed to elicit a useful biological response at its interface, notably bonding with bone for some compositions and uses. It is a class of biomaterials, not a claim that every glass has the same response. Related glass-ceramics contain crystalline phases and should be distinguished from wholly glassy materials.

A motivating early experiment compared glass-ceramic solubility and interfacial hydroxyapatite crystallization with observations around implants in rat femurs. Larry L. Hench and colleagues examined histology and ultrastructure as well as laboratory interfacial changes. The question was how bonding developed at the material–bone interface, beyond the bulk material's mechanical strength.^[ref]

Contact with fluid can change the material's surface and release dissolved constituents. Geometry therefore matters alongside composition. For an original monodisperse spherical-powder model, radius $r$ and density $\rho$ give surface area per massAt stipulated $\rho =2500\mathrm{kg}{\mathrm{m}}^{-3}$ and $r=10\mu \mathrm{m}$, this is $120{\mathrm{m}}^2\mathrm{k}{\mathrm{g}}^{-1}$, or $0.12{\mathrm{m}}^2{\mathrm{g}}^{-1}$. Increasing radius to $100\mu \mathrm{m}$ reduces that area per mass tenfold. The example neglects pores and aggregation and is not a particular product's specification.

If initial release flux per unit area were equal in two such powders, their initial release rates per mass would differ by the same factor. Actual flux can change with solution composition and surface evolution; a biological response need not scale linearly with geometric area. Comparisons should therefore specify particle dimensions, exposed area, fluid conditions and time. Surface-layer formation, cytotoxicity, mechanical behavior and tissue bonding remain distinct observations rather than interchangeable proof of suitability.

Biocompatibility is the ability of a biomaterial to function with an appropriate response from the living system in a specified application. It relates the material, its intended function and its biological environment. It is therefore more informative to ask whether a particular finished component is compatible with a particular contact site and duration than to call a substance universally “biocompatible.”^[ref]

Consider the same nominal polymer used as a short-lived skin-contacting film or as part of a long-lived component contacting blood. Its chemistry alone does not specify the biological exposure. Surface treatment, processing residues, final preparation and the length and type of contact can change the relevant response. The FDA’s primary resource emphasizes the final finished device and explicitly identifies contact type, duration and component interactions as assessment variables.^[ref]

A cytotoxicity experiment addresses one part of this question by examining adverse effects on biological cells. In a simple illustrative cell culture comparison, suppose a sample-exposed culture has 900 viable cells and a matched control has 1000 at the same observation time. The relative viable-cell count is $900/1000=0.90$. That ratio is an observation under the chosen conditions, not a complete compatibility verdict: growth rate, exposure preparation, measurement method and repeatability affect its interpretation. A control can distinguish a material-associated effect from an effect of the culture medium or preparation procedure.

Functional compatibility also need not mean that nothing happens at the interface. Some biomaterials are designed to bond to bone, so the desired response differs from that of a material intended merely to remain separated from surrounding tissue. Evidence about cell viability, local tissue organization and the component’s mechanical function answers different questions. A useful experimental account states which response was measured, the biological setting and exposure history, and the uncertainty in the comparison.

In biomedical engineering, a biomaterial is a material selected or designed to interact with a biological system for a medical purpose. Its defining feature is this intended interaction, rather than whether it originated in an organism. A synthetic polymer, a metal or a ceramic can therefore be a biomaterial; natural collagen can also be processed for such a use. The biomedical meaning should be distinguished from the broader use of “bio” to mean material obtained from biomass.^[ref]

A biomaterial has both a material function and a biological environment. A load-bearing component must transmit forces without unacceptable deformation, but its surface also contacts fluid, proteins and biological cells. Biocompatibility consequently concerns an appropriate host response for a particular application; it is not a universal label that guarantees identical behavior at every site or for every exposure duration.^[ref]

An illuminating historical example is the 1971 work of L. L. Hench and colleagues on a bone-bonding glass-ceramic. They compared laboratory measurements of glass-ceramic solubility and interfacial hydroxyapatite crystallization with histology and ultrastructure observations around implants in rat femurs. The important question was how the material–bone interface developed, rather than merely whether the bulk ceramic was strong.^[ref]

To separate bulk behavior from an interface effect in a model experiment, one could compare specimens with identical dimensions and bulk Young's modulus but different surface treatments, while holding the cell culture conditions fixed. Measure both the mechanical response and cell adhesion, instead of substituting one for the other. Conversely, changing specimen thickness while retaining the same surface can change bending resistance without changing the nominal surface chemistry. These controlled comparisons show why evaluating a biomaterial requires specifying the material, its geometry, its interface and the biological setting together.

A biomedical engineer develops, investigates or evaluates systems at the intersection of engineering, biology and medicine. Work can include instrument design, biomechanics, biomaterials, data analysis and technical support for medical equipment. The role includes constructing models and experiments, not only assembling a finished device.^[ref]

An original load cell example makes the measurement work concrete. Suppose reference loads $F=2\mathrm{N}$ and $6\mathrm{N}$ produce outputs $V=0.30\mathrm{V}$ and $0.70\mathrm{V}$. Fitting the stipulated linear measurement model $V=kF+b$ givesA later output of $0.50\mathrm{V}$ then corresponds to $4\mathrm{N}$. Ignoring the offset would instead report $5\mathrm{N}$. With the calibration coefficients held fixed, an output uncertainty of $0.01\mathrm{V}$ contributes $0.10\mathrm{N}$ to force uncertainty; uncertainty in the reference loads and fitted coefficients adds further terms.

The engineer must also determine whether that model remains useful. A third reference load tests interpolation; repeated loading and unloading can reveal hysteresis; a temperature change can expose drift. Mounting the sensor on a biological specimen can alter the load path compared with the calibration fixture. Thus a satisfactory calibration curve is one part of demonstrating fitness for the intended measurement. Collaborating with users and reporting the conditions and limitations connects engineering performance to the biological question.

Biomedical engineering applies engineering analysis, measurement and design to problems in biology, medicine and health care. It includes instruments for medical imaging, devices that interact mechanically with the body, biomaterials and tissue engineering. The National Library of Medicine's scope connects experimental and analytical engineering methods with devices, materials, processes and systems for biology and medicine.^[ref]

A useful research example combines tensile testing with Raman spectroscopy. A mechanical tester mounted on a Raman microprobe stage held hydrated bone specimens while their mineral spectra were measured during elastic loading. The apparatus connected macroscopic deformation to a molecular-scale observation.^[ref] Neither measurement alone describes every property of the biological system.

For an original device-mechanics example, model a uniform elastic test strip of length $L$, area $A$ and Young's modulus $E$. Under axial force $F$, the small-extension model givesWith $F=10\mathrm{N}$, $L=20\mathrm{mm}$, $A=2\mathrm{m}{\mathrm{m}}^2$ and $E=1\mathrm{GPa}$, the predicted extension is $0.10\mathrm{mm}$. Doubling area halves that extension without changing material stiffness. These stipulated values illustrate a design calculation, not a device recommended for use in a patient.

The model must be tested against relevant biological conditions. Hydration, loading rate, tissue interfaces and biocompatibility can matter alongside stiffness. Bench measurements establish behavior under their test conditions; evidence that a device achieves a clinical benefit requires a separate assessment. A biomedical engineer connects the physical model, the measurement and the intended biological function.

David H. Kohn is a biomedical engineer whose research connects biomineralization, biomaterials and biomechanics. His University of Michigan profile describes two related questions: how the organization of mineralized tissue produces its mechanical behavior, and how understanding natural material formation can inform engineered biomaterials. This is an example of biomimetics: learning design principles from biological structures rather than merely copying their chemical ingredients.^[ref]

His joint work with M. D. Morris, W. F. Finney and Rupak M. Rajachar used Raman spectroscopy to investigate bone during elastic deformation. Their custom mechanical tester fitted the stage of a Raman microprobe and accepted hydrated specimens. The experiment paired loading of murine femora in tension with measurements of mineral phosphate-band shifts, while keeping loading below yield.^[ref] The combination asks how a local molecular response accompanies the deformation of an entire composite material.

An original idealized calculation explains why the two measurements are complementary. For a harmonic oscillator with effective bond force constant $k$ and reduced mass $\mu$, the vibrational wavenumber iswhere $c$ is the speed of light. Holding $\mu$ fixed gives the first-order relation $\Delta \tilde{\nu }/\tilde{\nu }\simeq \frac{1}{2}\Delta k/k$. A hypothetical band moving from $1000$ to $998\mathrm{c}{\mathrm{m}}^{-1}$ would correspond to approximately a $0.4\%$ decrease in this model's effective bond force constant. This Raman shift as a probe of bond stiffness is a local vibration model; the chosen numbers are not measurements from Kohn's paper.

A specimen's Young's modulus instead relates its macroscopic stress to its strain in a specified loading direction and regime. It cannot be read directly from one vibrational wavenumber. Composite material geometry, phase interactions and orientation mediate the connection between a local bond force constant and a bulk elastic modulus. Even a large local spectral response need not imply an equally large change in bulk stiffness.

This distinction gives the experiment its interest: a tensile testing apparatus and a spectroscopic probe observe different levels of the same loaded material. Their agreement or disagreement can discriminate structural explanations that a single bulk measurement would leave unresolved. Repeating both measurements during unloading would additionally test whether the changes reverse. Kohn's institutional description places this multiscale mechanics question alongside the development of new biomaterials.^[ref]

Endovascular surgery comprises interventions performed from within a blood vessel, commonly using catheters and imaging to reach and treat a vascular region. It differs in access and apparatus from an operation that directly exposes the entire treated segment. The field includes methods such as balloon angioplasty and placement of a vascular stent; the appropriate intervention depends on the clinical problem.^[ref]

An angiographic system combines vascular access with images of a contrast-filled vessel. The Society for Vascular Surgery describes an angiogram as potentially diagnostic or therapeutic, with balloon angioplasty and stent placement among the possible accompanying interventions.^[ref] The image supplies information about the lumen and device position, but an image of an apparently open region is not by itself a complete measurement of downstream tissue function.

A simple imaging example shows why geometry matters. In a bench phantom, suppose a marker of known length $5\mathrm{mm}$ spans 25 image pixels. At that marker’s plane, the scale is $0.20\mathrm{mm}$ per pixel, so an 18-pixel feature would represent $3.6\mathrm{mm}$ under the same projection conditions. Applying that scale to an object at a different depth can be wrong because magnification changes. These chosen values illustrate measurement calibration, not device sizing for a patient.

Fluoroscopy provides time-dependent projection images that help relate device motion to anatomy. Projection, motion, overlapping structures and image resolution limit what can be inferred from one view. A sound technical account therefore distinguishes the device’s mechanical action, the image measurement and the biological outcome.

The scientific questions extend beyond immediate access: how the intervention changes the flow pathway, how a device interacts with the vessel wall and whether the intended function persists. Those questions connect endovascular surgery to fluid dynamics, biomaterials, imaging and the measurement of clinical outcomes.

Larry L. Hench (1938–2015) was a materials scientist known for developing bioactive glass: a biomaterial designed to form a bond with living bone. The National Academy of Engineering memorial records his name, dates and contribution to bioactive glasses and glass corrosion.^[ref]

His own account explains the key experimental observation: early glass specimens implanted in rat femurs became bonded to bone. The scientific question was how the solid’s composition and its reactions with body fluid could create that interface. The proposed mechanism involved dissolution and formation of a mineral-rich surface layer, followed by biological attachment.^[ref] The earlier joint paper compared solubility and interfacial hydroxyapatite crystallization studies with implant histology and ultrastructure.^[ref]

This work changed the design question from simply finding a strong solid to understanding a solid–tissue system. A bond at the interface and sufficient bulk strength are distinct properties: a strong implant can still detach at its surface, while a bonded but weak material can fail internally. Testing where a loaded specimen separates helps distinguish these possibilities. That distinction connects Hench’s experimental approach to biocompatibility, biomechanics and tissue engineering.

Michel Vert chaired IUPAC's project on terminology for biorelated polymers and coauthored the resulting 2012 recommendations. The project explicitly addressed materials intended to function for a limited time in biomedical applications.^[ref] Its scientific motivation is to distinguish what happens to a material from what an application hopes it will do.

For example, hydrolysis of susceptible backbone bonds, diffusion of water into a specimen and escape of soluble fragments need not occur on the same timescale. A decrease in molecular size is not identical to complete removal of a device or its products from the body.

An original scale estimate compares water diffusion over distance $L$ with a first-order cleavage model. The characteristic times areChoose $L=1\mathrm{mm}$, $D=10^{-10}{\mathrm{m}}^2{\mathrm{s}}^{-1}$ and $k=10^{-6}{\mathrm{s}}^{-1}$. Then $t_D\sim 10^4\mathrm{s}$ while $t_R\sim 10^6\mathrm{s}$. Water can penetrate this idealized length before extensive cleavage. Reducing $D$ by a factor of $10^4$ reverses that ordering. The model neglects swelling, changing transport and reaction products; it illustrates why specimen dimensions and transport can alter degradation patterns even at a fixed reaction rate.

Testing a temporary biomaterial therefore needs separately defined observations: changes in molecular structure, retained mass, mechanical function and the fate of released products. These model comparisons explain the project motivation and are not clinical predictions or experimental values attributed to Vert.

R. J. Splinter is a coauthor of the 1971 investigation of bonding mechanisms at the interface of ceramic prosthetic materials. The publisher lists Splinter with the College of Engineering at the University of Florida.^[ref]

The study developed a model for the bond between a glass-ceramic biomaterial and bone. It related material solubility and interfacial hydroxyapatite crystallization to histology and ultrastructure observed around rat-femur implants. Its scientific significance lies in examining a changing interface: dissolving species and newly formed mineral can matter as much as the original solid surface. Comparing chemical observations with tissue structure provides a way to test this mechanism, rather than assuming that contact alone establishes a durable bond.^[ref]

Hench’s retrospective describes Ray Splinter as a medical student who later became a reconstructive surgeon; the original publication’s R. J. Splinter byline is retained without expanding its initials.^[ref]

Robert S. Langer is a chemical engineer whose work connects biomaterials, drug delivery and tissue engineering. His MIT departmental profile identifies these as research areas, linking the chemical properties of a material to the biological task it is intended to perform.^[ref]

Langer coauthored the primary artery-engineering report and work on surface treatment of polymer meshes for vascular cell culture.^[ref][ref] The mesh study illustrates an interface problem: changing a polymer surface can change initial cell attachment without requiring the whole material to have a different macroscopic shape.

The broader engineering idea is to treat a biological function as a design problem with several interacting constraints. A material intended to support a developing tissue must permit transport and cell adhesion as well as supply mechanical support. A drug delivery material additionally has a release history: the initial amount loaded does not specify how much becomes available at each time. These distinctions explain why material chemistry, geometry and the biological environment are studied together.

Rupak M. Rajachar is a biomedical engineer working across biomaterials and biomechanics. His University of Washington profile records an undergraduate degree in materials science at the University of Michigan in 1994, followed by biomedical-engineering graduate degrees in 2003 and postdoctoral work at Washington. Its research interests include biomaterials, mechanics of cells and tissues, and device design.^[ref]

Rajachar coauthored the study with M. D. Morris, W. F. Finney and David H. Kohn that tracked mineral responses in hydrated bone during elastic deformation. A mechanical tester mounted on a Raman microprobe stage allowed Raman spectroscopy and mechanical loading to be compared during the same experiment. The observed mineral response occurred below yield, so changes in the Raman spectrum were not confined to a specimen that had already failed.^[ref]

The composite material perspective explains why this is a useful combination. Constituent volume fractions by themselves do not specify how load passes through a heterogeneous specimen. An original two-phase rod calculation illustrates the point without modeling an actual bone. Give the constituents Young's moduli $E_1=40\mathrm{GPa}$ and $E_2=2\mathrm{GPa}$, and first-constituent volume fraction $\varphi =0.25$.

If equally long, perfectly connected constituent bars sit side by side and undergo the same axial strain, their forces add. The longitudinal rule of mixtures givesIf equal-area constituent segments instead lie in series along the loading direction, they carry the same axial stress and their extensions add. The isostress rule of mixtures givesThe same constituent Young's moduli and volume fractions produce very different axial responses because their arrangement changes. These exact one-dimensional rod models assume small elastic deformation and compatible connections; they do not account for the geometry, interfaces or full elastic tensors of biological tissue.

The lesson for interpreting a coupled experiment is that a molecular measurement and a macroscopic stress-strain curve answer complementary questions. A Raman spectrum can reveal changes in a particular vibrating component, while mechanical loading probes the response of the assembled composite material. A credible interpretation has to explain their relation instead of treating either as a complete description of material quality. This provides a concrete materials-mechanics connection to the biomaterials and tissue-mechanics interests documented in Rajachar's institutional profile.^[ref]

T. K. Greenlee is a coauthor of the 1971 study of bonding between a glass-ceramic biomaterial and bone. The publisher’s byline lists Greenlee at the Veterans Administration Hospital in Gainesville, Florida.^[ref]

The study connected an interfacial chemical model with observations in biological tissue. Laboratory studies of material solubility and hydroxyapatite crystallization were compared with histology and ultrastructure around implants in rat femurs. This comparison addresses a concrete problem: a material can have suitable bulk mechanical properties while developing an unsuitable interface with living bone. Microscopic observations of that interface help test a proposed bonding mechanism instead of inferring it from bulk strength alone.^[ref]

In his historical account, Larry L. Hench identifies Greenlee as an orthopaedic surgeon involved in the early work.^[ref]

A vascular stent is a tubular implant providing radial support inside a blood vessel or vascular graft. Unlike a bypass graft, it supports the existing route. Support is a mechanical function; sustained patency is an outcome to measure.^[ref]

A balloon-expandable vascular stent retains its enlarged shape after balloon deflation. A self-expanding vascular stent enlarges after release from its constrained delivery configuration, through material properties, geometry or both.^[ref]

Stent recoil gives a simple worked measurement. If bench imaging measures diameter $d_{\mathrm{expanded}}$ during expansion and $d_{\mathrm{released}}$ after balloon deflation, defineFor illustrative diameters $3.0\mathrm{mm}$ and $2.8\mathrm{mm}$, recoil is about $6.7\%$. The lumen area falls by about $12.9\%$ if both sections are circular, since area scales with diameter squared. Neither percentage alone predicts the change in pulsatile blood flow.

Bench radial-compression tests record diameter against external pressure. Loading and unloading distinguish reversible response from permanent damage; cycling probes mechanical fatigue. The FDA engineering guidance separately considers microscopy and durability tests. These measurements connect vascular stents to biomechanics and biomaterials; bench performance does not establish clinical effectiveness.^[ref]

W. C. Allen is a coauthor of the 1971 paper on a bone-bonding glass-ceramic. The primary publisher record associates Allen with the College of Engineering at the University of Florida.^[ref]

The joint work examined how a biomaterial could develop a bond with bone, combining glass-ceramic solubility and interfacial hydroxyapatite crystallization studies with implant histology and ultrastructure. The example illustrates why designing a biomaterial requires more than selecting a high-strength material: interfacial reactions and the surrounding biological response can control how a mechanical load is transmitted. The publication compares laboratory interfacial evidence with tissue observations rather than treating every implant interface as chemically inert.^[ref]

Hench’s retrospective describes the collaborator Bill Allen as an orthopaedic surgeon; the 1971 source byline is retained here as W. C. Allen.^[ref]

William Martin Abbott was a vascular surgeon and investigator at Massachusetts General Hospital. The Society for Vascular Surgery’s primary memorial records his full name, his laboratory and clinical work, and his 1992 society presidency.^[ref]

Abbott participated in the collaboration that grew functional arteries in vitro; the follow-up paper identifies William Abbott with the MGH Department of Surgery.^[ref][ref] This work connects vascular surgery to biomaterials and tissue engineering: a replacement vessel must support blood flow and withstand mechanical loading while interacting with biological tissue.

For example, pressure resistance and the ability to retain a surgical connection are distinct mechanical requirements. A strong tube can still fail at its connection, and a mechanically intact tube does not by itself demonstrate sustained flow through an open lumen. Separating those outcomes makes a laboratory evaluation more informative than a single strength measurement. Abbott’s combined clinical and investigative career placed such questions at the interface of surgical function and engineered materials.